COMMUNIQUÉS West-GlobeNewswire

Goodness Growth Holdings to Release First Quarter 2024 Results on May 7, 2024
30/04/2024
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and [...]
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
30/04/2024
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
30/04/2024
– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Phase 1 clinical trial supported by preclinical profile demonstrating high [...]
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
30/04/2024
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- [...]
Inspire Medical Systems, Inc. to Present at the BofA Securities 2024 Health Care Conference
30/04/2024
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
30/04/2024
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first [...]
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
30/04/2024
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. [...]
Route 92 Medical Announces FDA 510(k) Clearance for FreeClimb 54 Reperfusion System
30/04/2024
SAN MATEO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today [...]
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
30/04/2024
Independent Safety Committee approves increase of RECCE ® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects, with dosing to start in near weeks R327 dosed at 3,000mg has successfully been [...]
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
30/04/2024
ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent [...]
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
30/04/2024
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage [...]
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
30/04/2024
Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related Behaviors REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno [...]
OrthoSelect announces release of DIBS AI® 8.0 with significant new features to speed and simplify digital indirect bonding for orthodontists
30/04/2024
AMERICAN FORK, Utah, April 30, 2024 (GLOBE NEWSWIRE) -- OrthoSelect, a leading orthodontics software company and digital orthodontics laboratory, announces the release of DIBS AI 8.0. Already an innovator in digital [...]
Appendix 4C & Quarterly Business Update – March 2024
30/04/2024
Launching our most comprehensive test and expanding into new global markets MELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader [...]
SIRPant Immunotherapeutics to Participate in Wells Fargo Virtual Private Biotech Symposium
30/04/2024
HUMMELSTOWN, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment [...]
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
30/04/2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting [...]
Alignment Healthcare to Present at Two Investor Conferences in May 2024
30/04/2024
ORANGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will present at the following [...]
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
30/04/2024
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today [...]
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
30/04/2024
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 [...]

Pages